Treatment of Intractable Cancer Pain with Resiniferatoxin - An Interim Study

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Advanced cancer frequently causes refractory pain, challenging current treatments.
• Resiniferatoxin (RTX), a TRPV1 agonist, targets specific neurons to interrupt pain signaling.
• Evaluating RTX offers a potential nonopioid alternative for severe cancer pain.

Purpose of the Study:

• To assess the safety and efficacy of intrathecal resiniferatoxin (RTX) in patients with refractory cancer pain.
• To evaluate RTX as a nonopioid analgesic for intractable pain management.
• To determine the impact of RTX on pain intensity and opioid consumption.

Main Methods:

• Phase 1, open-label, first-in-human study involving 19 patients with refractory cancer pain.
• Single intrathecal dose of RTX administered to patients with abdominal and/or lower extremity pain.
• Safety assessed via treatment-emergent adverse events; efficacy measured by pain intensity (numerical rating scale) and opioid consumption (morphine equivalents).

Main Results:

• 38% reduction in worst pain intensity and 57% decrease in opioid consumption observed post-RTX treatment.
• Common adverse events included sensory loss and urinary retention; 9 deaths occurred, consistent with advanced cancer progression.
• Transient electrocardiographic QT interval changes were noted in 5 patients, resolving within 24 hours.

Conclusions:

• Intrathecal RTX provides a single-administration, opioid-sparing analgesic effect for intractable cancer pain.
• The study observed expected and unexpected adverse events, with an encouraging initial impact on pain relief.
• RTX represents a potential novel therapeutic strategy for managing refractory cancer pain, warranting further investigation.